
Molecular oncology investigates the genetic, epigenetic, and biochemical alterations driving cancer initiation, progression, and resistance to therapy. This domain integrates high-throughput sequencing, molecular diagnostics, and targeted therapeutics to elucidate oncogenic pathways, tumor suppressor gene inactivation, and tumor microenvironment interactions. Advances in molecular profiling, biomarker discovery, and precision medicine redefine cancer classification and treatment strategies. Our following compilation presents the latest peer-reviewed publications and patented innovations, reflecting cutting-edge research on oncogenes, signal transduction, cancer stem cells, immunomodulation, and molecular imaging techniques essential for translational oncology and clinical applications.
This is our latest selection of worldwide publications and patents in english on Molecular Oncology, between many scientific online journals, classified and focused on oncogene, tumor suppresso, signal transduction pathway, cancer genomic, epigenetics in cancer, molecular biomarker, targeted cancer therapy, cancer cell signaling, DNA mutation, microRNAs in oncology, cancer stem cell, apoptosis regulation, tumor microenvironment, cancer immunotherapy, gene expression profil, chromosomal aberration, molecular diagnostic, cancer proteomic, oncogenic pathway, cancer metastasis, molecular mechanisms of carcinogenesis, tumor heterogeneity, cancer epigenomic, oncogenic viruse, molecular targeted drug, cancer transcriptomics, DNA repair mechanism, cancer pharmacogenomic and cancer molecular patholog.
A perspective on gene expression and regional brain sensitivity
Published on 2026-07-08 by @MIT
Abstract: AbstractNon-invasive transcranial ultrasound stimulation (TUS) enables deep brain therapeutic exploration at unprecedented scale. However, its optimal use is limited by the uncertainty surrounding ultrasound sensitivity across brain regions and cell types. This uncertainty often forces selection of sub-optimal parameter–target treatment paradigms guided solely by precedent, rather than an unbiased search of the larger combinatorial space. In principle, human brain-wide gene expression data cou[...]
Our summary: This perspective discusses the use of gene expression data to enhance transcranial ultrasound stimulation (TUS) parameter selection. It highlights the identification of regional gene expression clusters that may respond similarly to TUS. The findings emphasize the importance of optimizing stimulation parameters based on molecular profiles across different brain regions.
gene expression, transcranial ultrasound stimulation, brain regions, neuromodulation
Publication
Heterobifunctional compounds for the degradation of kras protein
Patent published on the 2026-07-02 in WO under Ref WO2026139448 by MERCK PATENT GMBH [DE] (Anderson Corey Don [us], Cheng Xinpeng [us])
Abstract: The invention provides compounds that degrade the Kirsten rat sarcoma viral oncogene homolog (KRAS) protein including mutant forms via the ubiquitination of the KRAS protein and subsequent proteasomal degradation. The compounds are useful for the treatment of various cancers.[...]
Our summary: The invention focuses on heterobifunctional compounds that target and degrade the KRAS protein, including its mutant forms. These compounds facilitate ubiquitination of KRAS, leading to its proteasomal degradation. They hold potential for treating various types of cancer.
Heterobifunctional compounds, KRAS protein, ubiquitination, proteasomal degradation
Patent
Chimeric antigen receptor fc-engineered granulocyte-monocyte progenitors for enhanced cancer immunotherapy
Patent published on the 2026-06-25 in WO under Ref WO2026136621 by UNIV SOUTHERN CALIFORNIA [US] (Majeti Ravindra [us], Ying Qi-long [us], Yue Shi [us])
Abstract: Provided herein are chimeric antigen receptors, comprising an extracellular domain capable of binding to an antigen, an Fc region, a flexible linker, a transmembrane domain, and may further comprise at least one intracellular domain that is designed to increase the anti-tumor activities of granulocytes, macrophages, and dendritic cells by increasing their phagocytosis and/or proinflammatory cytokines secretion and/or antigen presentation. Provided herein are vectors and nucleic acid molecules en[...]
Our summary: This content discusses the development of chimeric antigen receptors with Fc-engineering to enhance the anti-tumor activities of granulocyte-monocyte progenitors. It details methods for genetically engineering these progenitors to express the receptors and their potential differentiation into macrophages or granulocytes. The ultimate goal is to utilize these engineered cells in immunotherapy for cancer treatment.
chimeric antigen receptor, granulocyte-monocyte progenitors, cancer immunotherapy, Fc-engineering
Patent
Multifunctional molecules comprising soluble tcr fragments and uses thereof
Patent published on the 2026-06-18 in WO under Ref WO2026125496 by ENGIMMUNE THERAPEUTICS AG [CH] (Wehrle Sarah [ch], Lalevee SÉbastien [ch], Yang Qinmei [ch], Vazquez-lombardi Rodrigo [ch], Ehling Roy [ch], Crook Kenneth [ch], Kucharczyk Jakub [ch])
Abstract: The present invention is in the field of immunotherapy, in particular cancer immunotherapy and relates to multifunctional molecules comprising at least a soluble TCR fragment, a CD3 agonist, a CD2 agonist and optionally, an antibody Fc region. Furthermore, the invention relates to methods of making the multifunctional molecule according to the invention, as well as therapeutic uses thereof.[...]
Our summary: The invention describes multifunctional molecules that include soluble TCR fragments and CD3/CD2 agonists. These molecules are designed for applications in cancer immunotherapy. Methods for their production and therapeutic uses are also outlined.
multifunctional molecules, soluble TCR fragments, cancer immunotherapy, CD3 agonist
Patent
Lineage-loci engineered cell therapy and related methods of producing and using same
Patent published on the 2026-06-11 in WO under Ref WO2026123001 by UMOJA BIOPHARMA INC [US] (O'hara Samantha [us], Romanov Artem [us], Koning Ryan [us], Vereide David T [us], Yingst Ashley M [us], Jarrell Dillon [us])
Abstract: Provided herein are genetically engineered cells containing a payload in a lineage specific locus and related methods and uses thereof in cell therapy. In some embodiments, the cells are genetically engineered with a CAR, such that expression of the CAR is delayed until the cell is differentiated to a lineage. In some embodiments, the genetically modified cells can be selected for using a selection cassette. Also provided are cell compositions containing the engineered cells, and related methods[...]
Our summary: This content discusses lineage-loci engineered cell therapy and methods for producing genetically engineered cells. It highlights the use of CARs that are expressed upon cell differentiation. Additionally, it covers cell compositions, selection methods, and applications in cancer immunotherapy.
cell therapy, genetically engineered cells, CAR, lineage-specific locus
Patent
Tumor antigens for ovarian cancer and uses thereof
Patent published on the 2026-05-28 in WO under Ref WO2026107594 by UNIV DE MONTREAL [CA] (Perreault Claude [ca], Thibault Pierre [ca], Hardy Marie-pierre [ca], Vincent Krystel [ca])
Abstract: Ovarian cancer, notably high-grade serous ovarian cancer (HGSC), the principal cause of death from gynecological malignancies in the world, has not significantly benefited from recent progress in cancer immunotherapy. While HGSC infiltration by lymphocytes correlates with superior survival, the nature of antigens that can elicit anti-HGSC immune responses is still largely unknown. Novel tumor antigens shared by a large proportion of ovarian tumor cells are described herein. Several of the tumor [...]
Our summary: Novel tumor antigens for high-grade serous ovarian cancer are identified, derived from aberrantly expressed genomic sequences. These antigens are not present in normal tissues and may elicit immune responses. The study discusses their potential use in treatments, including nucleic acids, compositions, cells, and vaccines.
tumor antigens, ovarian cancer, immunotherapy, vaccines
Patent
A fluid processing device for processing droplets
Patent published on the 2026-05-06 in EP under Ref EP4737004 by IMEC VZW [BE] (Yurt Abdulkadir [be], Set Ying Ting [be], Moloudi Reza [be], Vandevelde Bart [be])
Abstract: [0001] The present invention relates to a fluid processing device for processing droplets. The device comprises a plate-like structure comprising a plurality of functional pixels. Each functional pixel is adapted to perform multiple operations on a droplet located on the pixel. Specifically, each pixel can selectively carry out at least two of the following processing operations: manipulating the droplet (e.g., its position), applying heat to the droplet, and subjecting the droplet to a magnetic[...]
Our summary: The invention is a fluid processing device designed for droplet manipulation. It features a plate-like structure with functional pixels that can perform multiple operations on droplets. This device integrates various microfluidic functions into a compact platform for applications in biochemical analysis and drug discovery.
microfluidics, droplet manipulation, functional pixels, biochemical analysis
Patent
Glioblastoma-Derived Extracellular Vesicles Modulate γδ T Lymphocytes Through a MIC-Dependent Mechanism
Published on 2026-02-03 by Micaela Rosato, Paula Saibene Vlez, Alejandra Infante Cruz, Matas A. Pibuel, Federico Fuentes, Mnica Vermeulen, Juan Iturrizaga, Pablo E. Espil, Silvia Berner, Gabriela V. Salamone, Carolina C. Jancic @MDPI
Abstract: Glioblastoma (GBM) is the most aggressive and common primary brain tumor, with a median survival of less than a year after diagnosis. γδ T lymphocytes are immune cells that can migrate to tumors and induce malignant cells’ apoptosis. Our previous in silico studies showed that higher γδ T-cell infiltration in GBM correlates with better patient survival, and in vitro experiments showed that GMB supernatants promote an antitumora[...]
Our summary: Glioblastoma-derived extracellular vesicles (EVs) modulate gamma delta T lymphocytes through a MIC-dependent mechanism. Increased CD69 expression, cytotoxicity, and cytokine production in T cells were observed following EV interaction. These findings offer insights for targeted immunotherapy development in glioblastoma patients.
Extracellular vesicles, Glioblastoma, Gamma delta T lymphocytes, Immunotherapy
Publication











